| NCT03364998 |
BAY94-9027 PK Study Comparing to Another Long Acting Product |
https://ClinicalTrials.gov/show/NCT03364998 |
Completed |
Bayer |
2018-01-25 |
| NCT03095287 |
Alphanate in Immune Tolerance Induction Therapy |
https://ClinicalTrials.gov/show/NCT03095287 |
Recruiting |
Grifols Therapeutics LLC |
2021-10-31 |
| NCT03995784 |
Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B |
https://ClinicalTrials.gov/show/NCT03995784 |
Completed |
Catalyst Biosciences |
2020-02-28 |
| NCT03588299 |
Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a “Shuttle”. |
https://ClinicalTrials.gov/show/NCT03588299 |
Recruiting |
Bayer |
2022-05-31 |
| NCT03407651 |
Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B |
https://ClinicalTrials.gov/show/NCT03407651 |
Completed |
Catalyst Biosciences |
2019-03-15 |
| NCT03380780 |
A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese Volunteers |
https://ClinicalTrials.gov/show/NCT03380780 |
Completed |
Hoffmann-La Roche |
2018-09-18 |
| NCT03379974 |
Exercise Versus DDAVP in Patients With Mild Hemophilia A |
https://ClinicalTrials.gov/show/NCT03379974 |
Completed |
Nationwide Children’s Hospital |
2019-08-30 |
| NCT03376516 |
Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A |
https://ClinicalTrials.gov/show/NCT03376516 |
Completed |
Octapharma |
2018-11-03 |
| NCT03370913 |
Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients |
https://ClinicalTrials.gov/show/NCT03370913 |
Active, not recruiting |
BioMarin Pharmaceutical |
2022-12-31 |
| NCT03370172 |
Safety and Dose Escalation Study of an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia A Participants |
https://ClinicalTrials.gov/show/NCT03370172 |
Active, not recruiting |
Shire |
2021-09-30 |
| NCT03369444 |
A Factor IX Gene Therapy Study (FIX-GT) |
https://ClinicalTrials.gov/show/NCT03369444 |
Recruiting |
University College, London |
2021-01-01 |
| NCT03485170 |
PET Imaging of Hemophilic Arthropathy |
https://ClinicalTrials.gov/show/NCT03485170 |
Completed |
Tri-Service General Hospital |
2018-12-31 |
| NCT03363321 |
PF-06741086 Long-term Treatment in Severe Hemophilia |
https://ClinicalTrials.gov/show/NCT03363321 |
Recruiting |
Pfizer |
2020-08-11 |
| NCT03307980 |
Long-term Safety and Efficacy Study of SPK-9001 in Individuals With Hemophilia B |
https://ClinicalTrials.gov/show/NCT03307980 |
Recruiting |
Pfizer |
2026-10-06 |
| NCT03272568 |
Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia Carriers |
https://ClinicalTrials.gov/show/NCT03272568 |
Completed |
Emory University |
2019-12-31 |
| NCT03205163 |
A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A) |
https://ClinicalTrials.gov/show/NCT03205163 |
Completed |
Bioverativ Therapeutics Inc. |
2018-11-12 |
| NCT03196297 |
A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors |
https://ClinicalTrials.gov/show/NCT03196297 |
Completed |
Novo Nordisk A/S |
2018-06-22 |
| NCT03196284 |
A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors |
https://ClinicalTrials.gov/show/NCT03196284 |
Completed |
Novo Nordisk A/S |
2018-09-19 |
| NCT03191799 |
A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors |
https://ClinicalTrials.gov/show/NCT03191799 |
Active, not recruiting |
Hoffmann-La Roche |
2020-09-04 |
| NCT03186677 |
Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B Patients |
https://ClinicalTrials.gov/show/NCT03186677 |
Completed |
ISU Abxis Co., Ltd. |
2018-10-10 |
| NCT03103542 |
Study of rFVIIIFc for ITI in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies |
https://ClinicalTrials.gov/show/NCT03103542 |
Active, not recruiting |
Swedish Orphan Biovitrum |
2019-09-04 |
| NCT03075670 |
A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B |
https://ClinicalTrials.gov/show/NCT03075670 |
Completed |
Novo Nordisk A/S |
2017-12-08 |
| NCT03054662 |
Non Substitutive Strategies to Improve Haemophilia Care in Developing Countries. Experience in Ivory Coast. |
https://ClinicalTrials.gov/show/NCT03054662 |
Completed |
Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
2018-12-31 |
| NCT03020160 |
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A |
https://ClinicalTrials.gov/show/NCT03020160 |
Active, not recruiting |
Hoffmann-La Roche |
2017-12-15 |
| NCT03003533 |
A Gene Transfer Study for Hemophilia A |
https://ClinicalTrials.gov/show/NCT03003533 |
Recruiting |
Spark Therapeutics |
2020-05-31 |
| NCT03001830 |
Gene Therapy for Haemophilia A. |
https://ClinicalTrials.gov/show/NCT03001830 |
Recruiting |
University College, London |
2020-12-31 |
| NCT02994407 |
Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia A |
https://ClinicalTrials.gov/show/NCT02994407 |
Completed |
Novo Nordisk A/S |
2018-10-15 |
| NCT02974855 |
PF-06741086 Multiple Dose Study in Severe Hemophilia |
https://ClinicalTrials.gov/show/NCT02974855 |
Completed |
Pfizer |
2018-12-03 |
| NCT02954575 |
Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A |
https://ClinicalTrials.gov/show/NCT02954575 |
Completed |
Octapharma |
2018-03-29 |
| NCT02941354 |
Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A |
https://ClinicalTrials.gov/show/NCT02941354 |
Completed |
Novo Nordisk A/S |
2017-06-20 |
| NCT02938585 |
Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A |
https://ClinicalTrials.gov/show/NCT02938585 |
Completed |
Novo Nordisk A/S |
2018-03-16 |
| NCT02920398 |
A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A |
https://ClinicalTrials.gov/show/NCT02920398 |
Completed |
Novo Nordisk A/S |
2017-04-07 |
| NCT02919800 |
A Single-dose, Dose-escalation Study of a Long-acting MOD-5014 in Healthy Adult Male |
https://ClinicalTrials.gov/show/NCT02919800 |
Completed |
OPKO Health, Inc. |
2018-02-21 |
| NCT02870452 |
Effectiveness of Psychological Interventions in Haemophilia |
https://ClinicalTrials.gov/show/NCT02870452 |
Completed |
University of Minho |
2018-12-31 |
| NCT02851082 |
Could Physical Activity Help to Counteract the Blood Haemophilia Disturbance? A Pilot Study. |
https://ClinicalTrials.gov/show/NCT02851082 |
Completed |
University Hospital, Toulouse |
2017-01-31 |
| NCT02847637 |
A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors |
https://ClinicalTrials.gov/show/NCT02847637 |
Active, not recruiting |
Hoffmann-La Roche |
2017-09-15 |
| NCT02825667 |
Effectiveness of the Myofascial Therapy in the Hemophilic Arthropathy of Ankle |
https://ClinicalTrials.gov/show/NCT02825667 |
Completed |
Real Fundación Victoria Eugenia |
2017-09-08 |
| NCT02803502 |
Does the Thrombin Generation Test Performed During the Pharmacokinetic Profile of the Substitutive Factor VIII Bring Benefits to the Personalized Treatment of Pediatric Patients and Adult Hemophilia A Patients Under Prophylaxis ? |
https://ClinicalTrials.gov/show/NCT02803502 |
Recruiting |
Brugmann University Hospital |
2020-07-31 |
| NCT02795767 |
A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors |
https://ClinicalTrials.gov/show/NCT02795767 |
Active, not recruiting |
Hoffmann-La Roche |
2018-04-30 |
| NCT02781766 |
TGA (Thrombin Generation Assay) and Prophylaxis in Haemophilia |
https://ClinicalTrials.gov/show/NCT02781766 |
Recruiting |
Hospices Civils de Lyon |
2019-09-08 |
| NCT02781233 |
A Progressive Resistance Training Program in Patients With Haemophilia |
https://ClinicalTrials.gov/show/NCT02781233 |
Completed |
University of Valencia |
2018-06-25 |
| NCT02764489 |
FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR) |
https://ClinicalTrials.gov/show/NCT02764489 |
Recruiting |
Shire |
2021-03-30 |
| NCT02727647 |
Comparison of Different Prophylaxis Regimens for Moderate to Severe Hemophilia A Pediatric Patients |
https://ClinicalTrials.gov/show/NCT02727647 |
Completed |
Chulalongkorn University |
2016-03-31 |
| NCT02716194 |
BAX 826 Dose-Escalation Safety Study |
https://ClinicalTrials.gov/show/NCT02716194 |
Completed |
Shire |
2017-01-17 |
| NCT02697370 |
Efficacy and Cost Effectiveness of Pharmacokinetic Dosing in Haemophilia A |
https://ClinicalTrials.gov/show/NCT02697370 |
Completed |
Hampshire Hospitals NHS Foundation Trust |
2015-05-31 |
| NCT02695160 |
Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B |
https://ClinicalTrials.gov/show/NCT02695160 |
Active, not recruiting |
Sangamo Therapeutics |
2021-01-31 |
| NCT02622321 |
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors |
https://ClinicalTrials.gov/show/NCT02622321 |
Active, not recruiting |
Hoffmann-La Roche |
2016-10-25 |
| NCT02615691 |
Safety, Immunogenicity and Hemostatic Efficacy of PEGylated Recombinant FVIII (BAX 855) in Previously Untreated Patients (PUPs) < 6 Years of Age With Severe Hemophilia A |
https://ClinicalTrials.gov/show/NCT02615691 |
Active, not recruiting |
Shire |
2023-06-29 |
| NCT02601170 |
Platelet-Rich Plasma Intra-Articular Injection in Treating Hemophilic Arthropathy |
https://ClinicalTrials.gov/show/NCT02601170 |
Completed |
Tri-Service General Hospital |
2015-04-30 |
| NCT02585960 |
BAX 855 PK-guided Dosing |
https://ClinicalTrials.gov/show/NCT02585960 |
Completed |
Shire |
2018-08-05 |
| NCT02582060 |
Individualizing Hemophilia Prophylaxis Using Thromboelastography |
https://ClinicalTrials.gov/show/NCT02582060 |
Completed |
Children’s Hospital Los Angeles |
2017-12-31 |
| NCT03093480 |
A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study) |
https://ClinicalTrials.gov/show/NCT03093480 |
Active, not recruiting |
Sanofi |
2021-02-15 |
| NCT02576795 |
Gene Therapy Study in Severe Haemophilia A Patients |
https://ClinicalTrials.gov/show/NCT02576795 |
Active, not recruiting |
BioMarin Pharmaceutical |
2022-02-28 |
| NCT03061201 |
Dose-Ranging Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 in Subjects With Severe Hemophilia A |
https://ClinicalTrials.gov/show/NCT03061201 |
Recruiting |
Pfizer |
2024-07-23 |
| NCT02571569 |
A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors |
https://ClinicalTrials.gov/show/NCT02571569 |
Completed |
Bayer |
2018-07-09 |
| NCT02554773 |
An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B |
https://ClinicalTrials.gov/show/NCT02554773 |
Active, not recruiting |
Sanofi |
2023-02-28 |
| NCT03392974 |
Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kg |
https://ClinicalTrials.gov/show/NCT03392974 |
Active, not recruiting |
BioMarin Pharmaceutical |
2022-12-01 |
| NCT02548143 |
LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures |
https://ClinicalTrials.gov/show/NCT02548143 |
Completed |
LFB USA, Inc. |
2017-08-06 |
| NCT02541942 |
Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adeptâ„¢2 Trial |
https://ClinicalTrials.gov/show/NCT02541942 |
Completed |
Novo Nordisk A/S |
2016-04-15 |
| NCT02528968 |
National Study of a Pharmacokinetic-Focused Educational Package for Patients With Severe Haemophilia A |
https://ClinicalTrials.gov/show/NCT02528968 |
Completed |
Hampshire Hospitals NHS Foundation Trust |
2017-11-30 |
| NCT02506023 |
Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers |
https://ClinicalTrials.gov/show/NCT02506023 |
Completed |
Emory University |
2018-06-15 |
| NCT02502149 |
Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale |
https://ClinicalTrials.gov/show/NCT02502149 |
Completed |
Bioverativ Therapeutics Inc. |
2017-04-30 |
| NCT02492984 |
PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A |
https://ClinicalTrials.gov/show/NCT02492984 |
Completed |
Pfizer |
2016-07-31 |
| NCT02490787 |
Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects |
https://ClinicalTrials.gov/show/NCT02490787 |
Completed |
Novo Nordisk A/S |
2016-10-14 |
| NCT02484092 |
A Gene Therapy Study for Hemophilia B |
https://ClinicalTrials.gov/show/NCT02484092 |
Completed |
Pfizer |
2019-04-08 |
| NCT02483208 |
Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate |
https://ClinicalTrials.gov/show/NCT02483208 |
Completed |
Bayer |
2015-07-31 |
| NCT02461992 |
Study of PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Male Chinese Subjects With Hemophilia A |
https://ClinicalTrials.gov/show/NCT02461992 |
Completed |
Pfizer |
2015-08-31 |
| NCT02418793 |
A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B |
https://ClinicalTrials.gov/show/NCT02418793 |
Completed |
OPKO Health, Inc. |
2018-09-30 |
| NCT02396342 |
Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B |
https://ClinicalTrials.gov/show/NCT02396342 |
Active, not recruiting |
UniQure Biopharma B.V. |
2021-05-31 |
| NCT02362581 |
Comparison of Prophylaxis and On-demand Treatment in Children With Moderate to Severe Hemophilia A |
https://ClinicalTrials.gov/show/NCT02362581 |
Completed |
Chulalongkorn University |
2014-01-31 |
| NCT02336178 |
Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in China |
https://ClinicalTrials.gov/show/NCT02336178 |
Completed |
Pfizer |
2016-07-31 |
| NCT02306694 |
Prospective Biomarkers of Bone Metabolism in Hemophilia A |
https://ClinicalTrials.gov/show/NCT02306694 |
Completed |
Oregon Health and Science University |
2018-04-16 |
| NCT02284789 |
Colorado Adult Joint Assessment Scale (CAJAS) Validation |
https://ClinicalTrials.gov/show/NCT02284789 |
Completed |
Bayer |
2015-10-31 |
| NCT02263469 |
A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Under the Age of 6 Years |
https://ClinicalTrials.gov/show/NCT02263469 |
Completed |
Bio Products Laboratory |
2006-07-31 |
| NCT02263456 |
A Study to Compare the Pharmacokinetics and Safety of Replenine®-VF, Replenine® or Other Factor IX in Haemophilia B |
https://ClinicalTrials.gov/show/NCT02263456 |
Completed |
Bio Products Laboratory |
2001-09-30 |
| NCT02250573 |
An Open-study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Subjects Undergoing Surgery |
https://ClinicalTrials.gov/show/NCT02250573 |
Completed |
Bio Products Laboratory |
2006-04-30 |
| NCT02250560 |
A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Undergoing Major Surgery. |
https://ClinicalTrials.gov/show/NCT02250560 |
Completed |
Bio Products Laboratory |
2003-11-30 |
| NCT02250482 |
An Open Study to Investigate the Safety and Efficacy of Optivate® in Haemophilia A Patients Undergoing Surgery. |
https://ClinicalTrials.gov/show/NCT02250482 |
Completed |
Bio Products Laboratory |
2003-08-31 |
| NCT02246894 |
A Study to Investigate the Safety and Efficacy of Optivate® in Children Under 6 Years of Age With Haemophilia A. |
https://ClinicalTrials.gov/show/NCT02246894 |
Completed |
Bio Products Laboratory |
2005-01-31 |
| NCT02246881 |
A Study to Compare the Pharmacokinetics and Safety of Current Factor VIII Concentrate and Optivate® in Haemophilia A. |
https://ClinicalTrials.gov/show/NCT02246881 |
Completed |
Bio Products Laboratory |
2004-01-31 |
| NCT02246868 |
An Open Study to Investigate the Safety and Efficacy of Optivate® in Severe Haemophilia A Patients. |
https://ClinicalTrials.gov/show/NCT02246868 |
Completed |
Bio Products Laboratory |
2004-08-31 |
| NCT02234323 |
An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia A |
https://ClinicalTrials.gov/show/NCT02234323 |
Completed |
Bioverativ Therapeutics Inc. |
2019-09-23 |
| NCT02234310 |
Study to Determine the Safety and Efficacy of rFIXFc in Untreated Males With Severe Hemophilia B |
https://ClinicalTrials.gov/show/NCT02234310 |
Completed |
Bioverativ Therapeutics Inc. |
2019-08-20 |
| NCT02231944 |
An Open Study to Investigate the Safety and Efficacy of Replenine®-VF in Severe Haemophilia B Patients |
https://ClinicalTrials.gov/show/NCT02231944 |
Completed |
Bio Products Laboratory |
2003-10-31 |
| NCT02213250 |
An Open-Label, Single Dose Pharmacokinetic Study of Benefix (Recombinant Factor IX) in Male Chinese Subjects With Hemophilia B |
https://ClinicalTrials.gov/show/NCT02213250 |
Completed |
Pfizer |
2015-04-30 |
| NCT02210091 |
BAX 855 Pediatric Study |
https://ClinicalTrials.gov/show/NCT02210091 |
Completed |
Shire |
2015-10-23 |
| NCT02198040 |
Physiotherapy in the Haemophilic Arthropathy of the Elbow. |
https://ClinicalTrials.gov/show/NCT02198040 |
Completed |
Universidad Católica San Antonio de Murcia |
2012-10-31 |
| NCT02198014 |
Manual Therapy in Haemophilic Arthropathy of the Knee |
https://ClinicalTrials.gov/show/NCT02198014 |
Completed |
Universidad Católica San Antonio de Murcia |
2012-10-31 |
| NCT02141074 |
Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B |
https://ClinicalTrials.gov/show/NCT02141074 |
Recruiting |
Novo Nordisk A/S |
2022-10-30 |
| NCT02093897 |
Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A |
https://ClinicalTrials.gov/show/NCT02093897 |
Completed |
CSL Behring |
2015-08-31 |
| NCT02083965 |
Pharmacokinetics of rFVIIIFc at Two Vial Strengths |
https://ClinicalTrials.gov/show/NCT02083965 |
Completed |
Bioverativ Therapeutics Inc. |
2014-10-31 |
| NCT03384277 |
Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab |
https://ClinicalTrials.gov/show/NCT03384277 |
Recruiting |
Institute of Hematology & Blood Diseases Hospital |
2021-10-30 |
| NCT01311648 |
BAY81-8973 Pediatric Safety and Efficacy Trial |
https://ClinicalTrials.gov/show/NCT01311648 |
Active, not recruiting |
Bayer |
2019-09-09 |
| NCT01288391 |
Investigating Safety and Pharmacokinetics of 2 Different Single Doses of NNC128-0000-2011 in Haemophilia A or B Patients |
https://ClinicalTrials.gov/show/NCT01288391 |
Completed |
Novo Nordisk A/S |
2011-07-31 |
| NCT01286779 |
BAX 326 (rFIX) Continuation Study |
https://ClinicalTrials.gov/show/NCT01286779 |
Completed |
Shire |
2017-06-29 |
| NCT01272206 |
Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male Subjects |
https://ClinicalTrials.gov/show/NCT01272206 |
Completed |
Novo Nordisk A/S |
2011-03-31 |
| NCT02035605 |
A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients |
https://ClinicalTrials.gov/show/NCT02035605 |
Completed |
Alnylam Pharmaceuticals |
2017-07-20 |
| NCT02020369 |
Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors |
https://ClinicalTrials.gov/show/NCT02020369 |
Completed |
rEVO Biologics |
2015-07-31 |
| NCT04158648 |
A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors |
https://ClinicalTrials.gov/show/NCT04158648 |
Recruiting |
Hoffmann-La Roche |
2022-07-19 |
| NCT03315455 |
Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants |
https://ClinicalTrials.gov/show/NCT03315455 |
Active, not recruiting |
Hoffmann-La Roche |
2021-03-09 |
| NCT01992549 |
Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII |
https://ClinicalTrials.gov/show/NCT01992549 |
Completed |
Octapharma |
2018-12-27 |
| NCT01949792 |
A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without Inhibitors |
https://ClinicalTrials.gov/show/NCT01949792 |
Completed |
Novo Nordisk A/S |
2013-11-30 |
| NCT01945593 |
BAX 855 Continuation |
https://ClinicalTrials.gov/show/NCT01945593 |
Completed |
Shire |
2018-03-02 |
| NCT01921855 |
Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors |
https://ClinicalTrials.gov/show/NCT01921855 |
Completed |
Bayer |
2009-12-31 |
| NCT01913405 |
Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures |
https://ClinicalTrials.gov/show/NCT01913405 |
Completed |
Shire |
2016-09-23 |
| NCT01863758 |
Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Patients With Severe Haemophilia A |
https://ClinicalTrials.gov/show/NCT01863758 |
Completed |
Octapharma |
2015-01-31 |
| NCT01810666 |
Prophylaxis Versus on Demand Treatment for Children With Hemophilia A |
https://ClinicalTrials.gov/show/NCT01810666 |
Completed |
Bayer |
2014-01-31 |
| NCT01800435 |
A Comparison Study of Bypassing Agent Therapy With and Without Tranexamic Acid in Haemophilia A Patients With Inhibitor |
https://ClinicalTrials.gov/show/NCT01800435 |
Completed |
Oslo University Hospital |
2012-10-31 |
| NCT01775618 |
Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A |
https://ClinicalTrials.gov/show/NCT01775618 |
Completed |
Bayer |
2015-03-19 |
| NCT01757405 |
Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen |
https://ClinicalTrials.gov/show/NCT01757405 |
Completed |
Shire |
2014-11-11 |
| NCT01748201 |
Viscosupplementation in Patients With Hemophilic Arthropathy |
https://ClinicalTrials.gov/show/NCT01748201 |
Completed |
University of Sao Paulo General Hospital |
2013-03-31 |
| NCT01736475 |
Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study) |
https://ClinicalTrials.gov/show/NCT01736475 |
Completed |
Shire |
2014-07-17 |
| NCT01731600 |
A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A |
https://ClinicalTrials.gov/show/NCT01731600 |
Completed |
Novo Nordisk A/S |
2014-09-15 |
| NCT01712438 |
Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients |
https://ClinicalTrials.gov/show/NCT01712438 |
Completed |
Octapharma |
2018-12-14 |
| NCT01708564 |
A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B |
https://ClinicalTrials.gov/show/NCT01708564 |
Completed |
rEVO Biologics |
2013-06-30 |
| NCT01704521 |
Viral Kinetics in HCV Clearance in Subjects With Hemophilia |
https://ClinicalTrials.gov/show/NCT01704521 |
Completed |
University of Cincinnati |
2014-10-31 |
| NCT01692925 |
Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia A |
https://ClinicalTrials.gov/show/NCT01692925 |
Completed |
Novo Nordisk A/S |
2013-03-31 |
| NCT01687608 |
Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B |
https://ClinicalTrials.gov/show/NCT01687608 |
Active, not recruiting |
Shire |
2030-10-28 |
| NCT01662531 |
A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B |
https://ClinicalTrials.gov/show/NCT01662531 |
Completed |
CSL Behring |
2014-10-31 |
| NCT01653639 |
Comparative Pharmacokinetic Study of Two Different Strengths of BAY14-2222 |
https://ClinicalTrials.gov/show/NCT01653639 |
Completed |
Bayer |
2012-12-31 |
| NCT01625390 |
A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150 |
https://ClinicalTrials.gov/show/NCT01625390 |
Completed |
Bayer |
2014-03-31 |
| NCT01599819 |
BAX 855 Dose-Escalation Safety Study |
https://ClinicalTrials.gov/show/NCT01599819 |
Completed |
Shire |
2012-08-31 |
| NCT01580293 |
A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A |
https://ClinicalTrials.gov/show/NCT01580293 |
Completed |
Bayer |
2014-06-13 |
| NCT01579903 |
Relative Bioavailability Of Two Formulations Of Moroctocog Alfa (AF-CC) |
https://ClinicalTrials.gov/show/NCT01579903 |
Completed |
Pfizer |
2013-01-31 |
| NCT01568580 |
Efficacy and Safety of Recombinant Factor VIII (GreenGene) in Patients With Hemophilia A |
https://ClinicalTrials.gov/show/NCT01568580 |
Completed |
Green Cross Corporation |
2006-09-30 |
| NCT01563471 |
Safety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy Volunteers |
https://ClinicalTrials.gov/show/NCT01563471 |
Completed |
Novo Nordisk A/S |
2002-07-31 |
| NCT01562587 |
Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State |
https://ClinicalTrials.gov/show/NCT01562587 |
Completed |
Novo Nordisk A/S |
2003-05-31 |
| NCT01561924 |
Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography |
https://ClinicalTrials.gov/show/NCT01561924 |
Completed |
Novo Nordisk A/S |
2006-05-31 |
| NCT01561417 |
Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects |
https://ClinicalTrials.gov/show/NCT01561417 |
Completed |
Novo Nordisk A/S |
2006-09-30 |
| NCT01561391 |
Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery |
https://ClinicalTrials.gov/show/NCT01561391 |
Completed |
Novo Nordisk A/S |
2004-05-31 |
| NCT01555749 |
Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects |
https://ClinicalTrials.gov/show/NCT01555749 |
Completed |
Novo Nordisk A/S |
2012-05-08 |
| NCT01507896 |
BAX 326 Surgery Study in Hemophilia B Patients |
https://ClinicalTrials.gov/show/NCT01507896 |
Completed |
Shire |
2014-05-15 |
| NCT01493778 |
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A |
https://ClinicalTrials.gov/show/NCT01493778 |
Completed |
Novo Nordisk A/S |
2017-08-16 |
| NCT01489111 |
Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A. |
https://ClinicalTrials.gov/show/NCT01489111 |
Completed |
Novo Nordisk A/S |
2018-12-10 |
| NCT01488994 |
BAX 326 Pediatric Study |
https://ClinicalTrials.gov/show/NCT01488994 |
Completed |
Shire |
2013-05-14 |
| NCT01486927 |
An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A |
https://ClinicalTrials.gov/show/NCT01486927 |
Completed |
CSL Behring |
2014-12-31 |
| NCT01480180 |
Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A |
https://ClinicalTrials.gov/show/NCT01480180 |
Completed |
Novo Nordisk A/S |
2018-12-10 |
| NCT01477437 |
Internet-based Educational Program to Promote Self-Management for Teens With Hemophilia |
https://ClinicalTrials.gov/show/NCT01477437 |
Completed |
The Hospital for Sick Children |
2013-03-31 |
| NCT01467427 |
Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B. |
https://ClinicalTrials.gov/show/NCT01467427 |
Active, not recruiting |
Novo Nordisk A/S |
2014-03-30 |
| NCT01458106 |
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A |
https://ClinicalTrials.gov/show/NCT01458106 |
Completed |
Bioverativ Therapeutics Inc. |
2013-12-31 |
| NCT01454739 |
Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A |
https://ClinicalTrials.gov/show/NCT01454739 |
Completed |
Bioverativ Therapeutics Inc. |
2017-10-31 |
| NCT01440946 |
Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B |
https://ClinicalTrials.gov/show/NCT01440946 |
Completed |
Bioverativ Therapeutics Inc. |
2014-11-30 |
| NCT01439971 |
Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia |
https://ClinicalTrials.gov/show/NCT01439971 |
Completed |
Catalyst Biosciences |
2015-10-31 |
| NCT01425723 |
Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B |
https://ClinicalTrials.gov/show/NCT01425723 |
Completed |
Bioverativ Therapeutics Inc. |
2017-10-31 |
| NCT01395810 |
Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773 |
https://ClinicalTrials.gov/show/NCT01395810 |
Completed |
Novo Nordisk A/S |
2014-03-30 |
| NCT01392547 |
Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors |
https://ClinicalTrials.gov/show/NCT01392547 |
Completed |
Novo Nordisk A/S |
2012-08-31 |
| NCT01386528 |
Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B |
https://ClinicalTrials.gov/show/NCT01386528 |
Completed |
Novo Nordisk A/S |
2013-12-01 |
| NCT01365520 |
A Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia A |
https://ClinicalTrials.gov/show/NCT01365520 |
Completed |
Novo Nordisk A/S |
2011-09-30 |
| NCT01361126 |
A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia B |
https://ClinicalTrials.gov/show/NCT01361126 |
Completed |
CSL Behring |
2012-06-30 |
| NCT01341912 |
Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTPs) |
https://ClinicalTrials.gov/show/NCT01341912 |
Completed |
Octapharma |
2012-08-31 |
| NCT01335061 |
Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia B |
https://ClinicalTrials.gov/show/NCT01335061 |
Completed |
Pfizer |
2014-04-30 |
| NCT01333111 |
Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients |
https://ClinicalTrials.gov/show/NCT01333111 |
Completed |
Novo Nordisk A/S |
2013-03-31 |
| NCT04396639 |
Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Hemophilia A Patients |
https://ClinicalTrials.gov/show/NCT04396639 |
Recruiting |
Pfizer |
2021-04-05 |
| NCT04394286 |
A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects |
https://ClinicalTrials.gov/show/NCT04394286 |
Recruiting |
Shire |
2024-03-16 |
| NCT04384341 |
Haemophilia and Bone Loss - PHILEOS Study |
https://ClinicalTrials.gov/show/NCT04384341 |
Recruiting |
Centre Hospitalier Universitaire de Saint Etienne |
2022-04-30 |
| NCT04309903 |
The Effects of Manual Therapy in Hemophilic Patients |
https://ClinicalTrials.gov/show/NCT04309903 |
Completed |
Necmettin Erbakan University |
2019-04-15 |
| NCT04308876 |
Effectiveness of Manual Therapy and Strengthening Exercises in Hemophilic Arthropathy of the Elbow Joint |
https://ClinicalTrials.gov/show/NCT04308876 |
Completed |
Necmettin Erbakan University |
2019-03-10 |
| NCT04303936 |
PHYSICAL ACTIVITY AND FVIII CLEARANCE: RELEVANCE FOR PERSONALIZED THERAPY IN SEVERE HAEMOPHILIA A (PHYSEMO) |
https://ClinicalTrials.gov/show/NCT04303936 |
Recruiting |
Catholic University of the Sacred Heart |
2020-12-30 |
| NCT04286412 |
Nonacog Alfa Prophylaxis And Treatment Of Bleeding Episodes In Previously Treated Patients With Hemophelia B |
https://ClinicalTrials.gov/show/NCT04286412 |
Recruiting |
Pfizer |
2020-11-05 |
| NCT04205188 |
The Effects of Therapeutic Exercises on Kinesiophobia in Haemophilic Patients. |
https://ClinicalTrials.gov/show/NCT04205188 |
Recruiting |
Cukurova University |
2019-12-13 |
| NCT04204408 |
A Research Study of How a New Medicine NNC0365-3769 (Mim8) Works in the Body of Healthy People and Patients With Bleeding Disorder |
https://ClinicalTrials.gov/show/NCT04204408 |
Recruiting |
Novo Nordisk A/S |
2021-03-09 |
| NCT04161495 |
A Phase 3, Open-label Interventional Study of an Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, BIVV001, in Patients With Severe Hemophilia A (XTEND-1) |
https://ClinicalTrials.gov/show/NCT04161495 |
Recruiting |
Sanofi |
2021-05-31 |
| NCT04135300 |
Gene Therapy for Chinese Hemophilia B |
https://ClinicalTrials.gov/show/NCT04135300 |
Recruiting |
Institute of Hematology & Blood Diseases Hospital |
2021-06-30 |
| NCT04133883 |
Impact on French Physician’s Haemophilia Treatment Management Decision Based on Systematic Joint Examination |
https://ClinicalTrials.gov/show/NCT04133883 |
Recruiting |
Swedish Orphan Biovitrum |
2022-02-28 |
| NCT04076306 |
What is the Feasibility of the ISTEP Exercise Test in Boys With Haemophilia |
https://ClinicalTrials.gov/show/NCT04076306 |
Completed |
Great Ormond Street Hospital for Children NHS Foundation Trust |
2018-11-02 |
| NCT04073498 |
The Safety and Tolerability of SerpinPC in Healthy Men and in Men With Severe Blood Disorders (Haemophilia A and B) |
https://ClinicalTrials.gov/show/NCT04073498 |
Recruiting |
ApcinteX Ltd |
2021-04-30 |
| NCT04072237 |
Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia |
https://ClinicalTrials.gov/show/NCT04072237 |
Active, not recruiting |
Catalyst Biosciences |
2020-04-30 |
| NCT04061109 |
Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A. |
https://ClinicalTrials.gov/show/NCT04061109 |
Recruiting |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2020-03-31 |
| NCT04060836 |
Pharmacokinetics Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A. |
https://ClinicalTrials.gov/show/NCT04060836 |
Recruiting |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2020-03-31 |
| NCT04046848 |
Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A |
https://ClinicalTrials.gov/show/NCT04046848 |
Active, not recruiting |
Octapharma |
2021-09-30 |
| NCT03974113 |
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B |
https://ClinicalTrials.gov/show/NCT03974113 |
Recruiting |
Sanofi |
2023-09-30 |
| NCT03935334 |
Clinical Trial Comparing a Biosimilar Eptacog Alfa With Novoseven, in Patients With Hemophilia With Inhibitors |
https://ClinicalTrials.gov/show/NCT03935334 |
Recruiting |
AryoGen Pharmed Co. |
2020-06-30 |
| NCT03915080 |
Optimizing the Use of Prophylaxis in Patients With Severe Haemophilia A |
https://ClinicalTrials.gov/show/NCT03915080 |
Recruiting |
Lund University |
2020-12-31 |
| NCT03914716 |
Imaging of Arthropathy in Boys With Hemophilia in China |
https://ClinicalTrials.gov/show/NCT03914716 |
Recruiting |
The Hospital for Sick Children |
2020-06-30 |
| NCT03861273 |
A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B |
https://ClinicalTrials.gov/show/NCT03861273 |
Recruiting |
Pfizer |
2021-11-26 |
| NCT03855696 |
A Study to Investigate the Safety, Tolerability, PK and PD of MG1113 in Healthy Subjects and Hemophilia Patients |
https://ClinicalTrials.gov/show/NCT03855696 |
Recruiting |
Green Cross Corporation |
2019-10-31 |
| NCT03855280 |
Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B |
https://ClinicalTrials.gov/show/NCT03855280 |
Recruiting |
Medexus Pharma, Inc. |
2021-08-01 |
| NCT03842605 |
Efficacy of Strength Training in Improving Elbow Range of Motion and Function in Adults With Hemophilia |
https://ClinicalTrials.gov/show/NCT03842605 |
Completed |
Oregon Health and Science University |
2019-02-28 |
| NCT03818763 |
Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A |
https://ClinicalTrials.gov/show/NCT03818763 |
Recruiting |
Medical College of Wisconsin |
2023-05-01 |
| NCT03815318 |
Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia A |
https://ClinicalTrials.gov/show/NCT03815318 |
Completed |
Sinocelltech Ltd. |
2020-01-16 |
| NCT03754790 |
Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX |
https://ClinicalTrials.gov/show/NCT03754790 |
Recruiting |
Sanofi |
2026-01-31 |
| NCT03734588 |
Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors |
https://ClinicalTrials.gov/show/NCT03734588 |
Active, not recruiting |
Spark Therapeutics |
2020-05-31 |
| NCT03700229 |
Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A |
https://ClinicalTrials.gov/show/NCT03700229 |
Recruiting |
Peking Union Medical College Hospital |
2019-10-15 |
| NCT03641703 |
A Long-Term Follow-Up Study of Haemophilia B Patients Who Have Undergone Gene Therapy |
https://ClinicalTrials.gov/show/NCT03641703 |
Recruiting |
Freeline Therapeutics |
2035-12-31 |
| NCT03622476 |
Pharmacokinetic (PK)Research on Chinese Children of Hemophilia |
https://ClinicalTrials.gov/show/NCT03622476 |
Recruiting |
Beijing Children’s Hospital |
2021-07-30 |
| NCT03615053 |
Personalized Medicine for Canadians With Hemophilia |
https://ClinicalTrials.gov/show/NCT03615053 |
Recruiting |
McMaster University |
2021-09-30 |
| NCT03598725 |
Low-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in China |
https://ClinicalTrials.gov/show/NCT03598725 |
Recruiting |
Beijing Children’s Hospital |
2019-12-01 |
| NCT03587116 |
Six Month lead-in Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%) |
https://ClinicalTrials.gov/show/NCT03587116 |
Recruiting |
Pfizer |
2021-09-24 |
| NCT03574922 |
The Effects of Core Stabilization Exercises in Addition to Balance Exercises in Adult Hemophilia Patients on Balance, Quality of Life, Lower Limb Muscle Strength and Functional Level |
https://ClinicalTrials.gov/show/NCT03574922 |
Completed |
Hacettepe University |
2019-02-01 |
| NCT03569891 |
HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients |
https://ClinicalTrials.gov/show/NCT03569891 |
Active, not recruiting |
UniQure Biopharma B.V. |
2020-09-30 |
| NCT03549871 |
A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis |
https://ClinicalTrials.gov/show/NCT03549871 |
Recruiting |
Sanofi |
2022-03-31 |
| NCT03529474 |
Psychology and Physiotherapy Approach of Chronic Pain in Patients With Hemophilia |
https://ClinicalTrials.gov/show/NCT03529474 |
Completed |
Instituto de Investigacion Sanitaria La Fe |
2019-03-15 |
| NCT03520712 |
Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5 |
https://ClinicalTrials.gov/show/NCT03520712 |
Enrolling by invitation |
BioMarin Pharmaceutical |
2025-06-30 |
| NCT03507582 |
Virtual Reality for Hemophilia |
https://ClinicalTrials.gov/show/NCT03507582 |
Completed |
Nationwide Children’s Hospital |
2016-12-28 |
| NCT03489291 |
Dose Confirmation Trial of AAV5-hFIXco-Padua |
https://ClinicalTrials.gov/show/NCT03489291 |
Active, not recruiting |
UniQure Biopharma B.V. |
2018-10-30 |
| NCT03481946 |
A Study to Assess Pharmacokinetics and Pharmacodynamics Following Administration of BAY1093884 in Patients With Severe Hemophilia |
https://ClinicalTrials.gov/show/NCT03481946 |
Completed |
Bayer |
2018-10-17 |
| NCT03449342 |
Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks Period |
https://ClinicalTrials.gov/show/NCT03449342 |
Completed |
Novo Nordisk A/S |
2019-03-25 |
| NCT03417245 |
A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors |
https://ClinicalTrials.gov/show/NCT03417245 |
Active, not recruiting |
Sanofi |
2021-04-30 |
| NCT03417102 |
A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors |
https://ClinicalTrials.gov/show/NCT03417102 |
Active, not recruiting |
Sanofi |
2020-12-31 |
| NCT01238367 |
A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543 |
https://ClinicalTrials.gov/show/NCT01238367 |
Completed |
Novo Nordisk A/S |
2011-10-31 |
| NCT01233440 |
Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia B |
https://ClinicalTrials.gov/show/NCT01233440 |
Completed |
CSL Behring |
2011-07-31 |
| NCT01233258 |
A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A |
https://ClinicalTrials.gov/show/NCT01233258 |
Completed |
Bayer |
2012-12-31 |
| NCT01229007 |
Study of Biostate® in Children With Hemophilia A |
https://ClinicalTrials.gov/show/NCT01229007 |
Completed |
CSL Behring |
2014-07-31 |
| NCT01228669 |
Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B |
https://ClinicalTrials.gov/show/NCT01228669 |
Completed |
Novo Nordisk A/S |
2012-09-10 |
| NCT01205724 |
Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A |
https://ClinicalTrials.gov/show/NCT01205724 |
Completed |
Novo Nordisk A/S |
2011-04-30 |
| NCT01184820 |
Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration |
https://ClinicalTrials.gov/show/NCT01184820 |
Completed |
Bayer |
2011-10-10 |
| NCT01181128 |
Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A |
https://ClinicalTrials.gov/show/NCT01181128 |
Completed |
Bioverativ Therapeutics Inc. |
2012-08-31 |
| NCT01178294 |
Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A |
https://ClinicalTrials.gov/show/NCT01178294 |
Completed |
Shire |
2013-07-01 |
| NCT01174446 |
Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients |
https://ClinicalTrials.gov/show/NCT01174446 |
Completed |
Shire |
2012-05-03 |
| NCT01138501 |
Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A |
https://ClinicalTrials.gov/show/NCT01138501 |
Completed |
Novo Nordisk A/S |
2011-11-30 |
| NCT01128881 |
IMMUNINE Pre-Treatment Study |
https://ClinicalTrials.gov/show/NCT01128881 |
Completed |
Shire |
2012-08-31 |
| NCT01125813 |
Efficacy and Safety Study of Human-cl rhFVIII in PTPs With Severe Hemophilia A |
https://ClinicalTrials.gov/show/NCT01125813 |
Completed |
Octapharma |
2012-01-31 |
| NCT01090206 |
Correlation Between Vitamin D Status and Bone Mineral Density in Patients With Hemophilia |
https://ClinicalTrials.gov/show/NCT01090206 |
Completed |
Virginia Commonwealth University |
2013-03-31 |
| NCT01085344 |
Canadian Hemophilia Prophylaxis Study |
https://ClinicalTrials.gov/show/NCT01085344 |
Completed |
The Hospital for Sick Children |
2012-12-31 |
| NCT01064284 |
Survey of Inhibitors in Plasma-Product Exposed Toddlers |
https://ClinicalTrials.gov/show/NCT01064284 |
Completed |
Fondazione Angelo Bianchi Bonomi |
2015-05-31 |
| NCT01051544 |
Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive |
https://ClinicalTrials.gov/show/NCT01051544 |
Active, not recruiting |
City of Hope Medical Center |
2020-06-30 |
| NCT01051076 |
Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced) |
https://ClinicalTrials.gov/show/NCT01051076 |
Active, not recruiting |
City of Hope Medical Center |
2020-06-30 |
| NCT01029340 |
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A |
https://ClinicalTrials.gov/show/NCT01029340 |
Completed |
Bayer |
2012-06-30 |
| NCT01027377 |
Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A |
https://ClinicalTrials.gov/show/NCT01027377 |
Completed |
Bioverativ Therapeutics Inc. |
2010-07-31 |
| NCT01027364 |
Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B |
https://ClinicalTrials.gov/show/NCT01027364 |
Completed |
Bioverativ Therapeutics Inc. |
2012-07-31 |
| NCT00994929 |
Efficacy and Safety of IL-11 in DDAVP Unresponsive |
https://ClinicalTrials.gov/show/NCT00994929 |
Completed |
University of Pittsburgh |
2012-04-30 |
| NCT00989196 |
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A |
https://ClinicalTrials.gov/show/NCT00989196 |
Completed |
Octapharma |
2011-10-31 |
| NCT00984126 |
Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015 |
https://ClinicalTrials.gov/show/NCT00984126 |
Completed |
Novo Nordisk A/S |
2016-06-28 |
| NCT00979238 |
Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B |
https://ClinicalTrials.gov/show/NCT00979238 |
Active, not recruiting |
St. Jude Children’s Research Hospital |
2032-06-12 |
| NCT00956345 |
Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B |
https://ClinicalTrials.gov/show/NCT00956345 |
Completed |
Novo Nordisk A/S |
2010-07-31 |
| NCT00952822 |
Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection |
https://ClinicalTrials.gov/show/NCT00952822 |
Completed |
Shire |
2009-10-31 |
| NCT00951873 |
A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Recombinant Human Factor VII in Healthy Male Volunteers |
https://ClinicalTrials.gov/show/NCT00951873 |
Completed |
Novo Nordisk A/S |
2010-04-30 |
| NCT00951405 |
Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors |
https://ClinicalTrials.gov/show/NCT00951405 |
Completed |
Novo Nordisk A/S |
2011-03-29 |
| NCT00950170 |
Study of Safety And Efficacy Of ReFacto AF In Previously Untreated Hemophilia A Patients In The Usual Care Setting |
https://ClinicalTrials.gov/show/NCT00950170 |
Completed |
Pfizer |
2016-11-24 |
| NCT00927667 |
Joint Status in Subjects With Severe Hemophilia A in Relation to Different Treatment Regimens |
https://ClinicalTrials.gov/show/NCT00927667 |
Completed |
Bayer |
2010-12-31 |
| NCT00922792 |
Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and B |
https://ClinicalTrials.gov/show/NCT00922792 |
Completed |
Novo Nordisk A/S |
2009-09-30 |
| NCT00914459 |
Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients |
https://ClinicalTrials.gov/show/NCT00914459 |
Completed |
Pfizer |
2016-03-31 |
| NCT00879541 |
Study of a pd vWF/FVIII, Biostate®, in Subjects With Haemophilia A |
https://ClinicalTrials.gov/show/NCT00879541 |
Completed |
CSL Behring |
2010-10-31 |
| NCT00916032 |
Pharmacokinetic Study of ADVATE 3000 IU in Previously Treated Patients With Severe Hemophilia A |
https://ClinicalTrials.gov/show/NCT00916032 |
Completed |
Shire |
2010-04-30 |
| NCT00868530 |
Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects |
https://ClinicalTrials.gov/show/NCT00868530 |
Completed |
Pfizer |
2009-12-31 |
| NCT00866606 |
Study Evaluating On-Demand Treatment With BeneFIX In Chinese Subjects |
https://ClinicalTrials.gov/show/NCT00866606 |
Completed |
Wyeth is now a wholly owned subsidiary of Pfizer |
2009-12-31 |
| NCT00851721 |
Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor |
https://ClinicalTrials.gov/show/NCT00851721 |
Completed |
Shire |
2012-10-31 |
| NCT00840086 |
Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects |
https://ClinicalTrials.gov/show/NCT00840086 |
Completed |
Novo Nordisk A/S |
2011-09-30 |
| NCT00839202 |
Activity and Content of Factor VIII (FVIII) in Human Plasma: The Assessment of a Novel Immunoassay |
https://ClinicalTrials.gov/show/NCT00839202 |
Completed |
Children’s Hospital Los Angeles |
2008-09-30 |
| NCT03009591 |
Fascial Therapy in Elbow Hemophilic Arthropathy |
https://ClinicalTrials.gov/show/NCT03009591 |
Completed |
Real Fundación Victoria Eugenia |
2018-12-01 |
| NCT02825706 |
Educational Physiotherapy in Haemophilia |
https://ClinicalTrials.gov/show/NCT02825706 |
Completed |
Real Fundación Victoria Eugenia |
2012-10-31 |
| NCT00837356 |
Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A Subjects |
https://ClinicalTrials.gov/show/NCT00837356 |
Completed |
Novo Nordisk A/S |
2009-10-31 |
| NCT04015492 |
Study to Compare How the Body Distributes and Excretes the Drugs Jivi (BAY 94-9027) and Adynovi in Patients With Severe Hemophilia A (Bleeding Disorder Resulting From a Lack of Blood Clotting Factor VIII) |
https://ClinicalTrials.gov/show/NCT04015492 |
Completed |
Bayer |
2019-10-25 |
| NCT03947567 |
Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients. |
https://ClinicalTrials.gov/show/NCT03947567 |
Recruiting |
Sinocelltech Ltd. |
2025-04-01 |
| NCT01562457 |
Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State |
https://ClinicalTrials.gov/show/NCT01562457 |
Completed |
Novo Nordisk A/S |
2006-04-30 |
| NCT04085458 |
Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophila A (Post-marketing Investigation) |
https://ClinicalTrials.gov/show/NCT04085458 |
Recruiting |
Bayer |
2022-08-31 |
| NCT03938792 |
Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Patients With Severe Hemophilia A or B |
https://ClinicalTrials.gov/show/NCT03938792 |
Recruiting |
Pfizer |
2023-04-27 |
| NCT02172950 |
An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A |
https://ClinicalTrials.gov/show/NCT02172950 |
Active, not recruiting |
CSL Behring |
2025-07-01 |
| NCT02137850 |
Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A |
https://ClinicalTrials.gov/show/NCT02137850 |
Enrolling by invitation |
Novo Nordisk A/S |
2021-11-13 |
| NCT02053792 |
A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B |
https://ClinicalTrials.gov/show/NCT02053792 |
Active, not recruiting |
CSL Behring |
2021-09-30 |
| NCT03091751 |
Efficacy and Safety of AlphaNine Versus BeneFIX in Patients With Severe Hereditary Haemophilia B |
https://ClinicalTrials.gov/show/NCT03091751 |
Completed |
Grifols Biologicals, LLC |
2009-10-31 |
| NCT03528551 |
A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A |
https://ClinicalTrials.gov/show/NCT03528551 |
Active, not recruiting |
Novo Nordisk A/S |
2020-12-03 |
| NCT02256917 |
Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A |
https://ClinicalTrials.gov/show/NCT02256917 |
Completed |
Octapharma |
2018-09-30 |
| NCT01496274 |
A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B |
https://ClinicalTrials.gov/show/NCT01496274 |
Completed |
CSL Behring |
2014-07-31 |
| NCT02170402 |
China ADVATE PTP Study |
https://ClinicalTrials.gov/show/NCT02170402 |
Completed |
Shire |
2016-05-31 |
| NCT00768287 |
Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B |
https://ClinicalTrials.gov/show/NCT00768287 |
Completed |
Aptevo Therapeutics |
2013-03-31 |
| NCT00749476 |
Study Evaluating BeneFIX in Patients With Haemophilia B, Previously Treated With Plasma Derived Factor IX |
https://ClinicalTrials.gov/show/NCT00749476 |
Completed |
Wyeth is now a wholly owned subsidiary of Pfizer |
2009-01-31 |
| NCT00717626 |
Once-A-Day Prophylaxis for Youth and Young Adults With Severe Hemophilia A |
https://ClinicalTrials.gov/show/NCT00717626 |
Completed |
The Hospital for Sick Children |
2011-04-30 |
| NCT00716716 |
Phase I/IIa Study of FIXFc in Hemophilia B Patients |
https://ClinicalTrials.gov/show/NCT00716716 |
Completed |
Bioverativ Therapeutics Inc. |
2009-10-31 |
| NCT00707772 |
Pegasys® Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus Infection |
https://ClinicalTrials.gov/show/NCT00707772 |
Completed |
Baqiyatallah Medical Sciences University |
2009-09-30 |
| NCT00666406 |
Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia A |
https://ClinicalTrials.gov/show/NCT00666406 |
Completed |
Shire |
2009-08-31 |
| NCT00640289 |
Clinical Trial of Factor XIII (FXIII) Concentrate |
https://ClinicalTrials.gov/show/NCT00640289 |
Completed |
Children’s Hospital of Orange County |
2011-12-31 |
| NCT00638001 |
Impact of Conservative Treatment by Custom-made Orthoses in Patients With Haemophilic Ankle Arthropathy |
https://ClinicalTrials.gov/show/NCT00638001 |
Completed |
Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
2012-03-31 |
| NCT00632814 |
Russian Kogenate Pediatric Study |
https://ClinicalTrials.gov/show/NCT00632814 |
Completed |
Bayer |
2009-09-30 |
| NCT00629837 |
Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980 |
https://ClinicalTrials.gov/show/NCT00629837 |
Completed |
Bayer |
NA |
| NCT00623480 |
Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment |
https://ClinicalTrials.gov/show/NCT00623480 |
Completed |
Bayer |
2011-09-30 |
| NCT00606060 |
BAY14-2222 Continuous Infusion in Surgeries |
https://ClinicalTrials.gov/show/NCT00606060 |
Completed |
Bayer |
NA |
| NCT00586521 |
BAY14-2222 Prophylaxis and Joint Function Improvement (Adults) |
https://ClinicalTrials.gov/show/NCT00586521 |
Completed |
Bayer |
2008-03-31 |
| NCT00581126 |
Study Evaluating BENEFIX in Previously Treated Patients With Hemophilia B |
https://ClinicalTrials.gov/show/NCT00581126 |
Completed |
Wyeth is now a wholly owned subsidiary of Pfizer |
NA |
| NCT00571584 |
High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors |
https://ClinicalTrials.gov/show/NCT00571584 |
Completed |
Novo Nordisk A/S |
2004-03-31 |
| NCT00543439 |
Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII |
https://ClinicalTrials.gov/show/NCT00543439 |
Completed |
Pfizer |
2018-04-30 |
| NCT00486278 |
Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds |
https://ClinicalTrials.gov/show/NCT00486278 |
Completed |
Novo Nordisk A/S |
2010-06-30 |
| NCT00375323 |
Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation Activation |
https://ClinicalTrials.gov/show/NCT00375323 |
Completed |
Medical University of Vienna |
NA |
| NCT00364182 |
Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B |
https://ClinicalTrials.gov/show/NCT00364182 |
Completed |
Pfizer |
2010-10-31 |
| NCT00357656 |
Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery |
https://ClinicalTrials.gov/show/NCT00357656 |
Completed |
Shire |
2015-10-01 |
| NCT00323856 |
Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A |
https://ClinicalTrials.gov/show/NCT00323856 |
Active, not recruiting |
Grifols Biologicals, LLC |
2018-12-31 |
| NCT00289536 |
Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A |
https://ClinicalTrials.gov/show/NCT00289536 |
Completed |
Shire |
2007-04-30 |
| NCT00284193 |
Combination Therapy of Low Doses of rFVIIa and FEIBA for Severe Hemophilia A Patients With an Inhibitor to Factor VIII |
https://ClinicalTrials.gov/show/NCT00284193 |
Completed |
Sheba Medical Center |
2008-11-30 |
| NCT00279578 |
Clot Formation and Clot Stability in Patients With Severe Haemophilia A |
https://ClinicalTrials.gov/show/NCT00279578 |
Completed |
University of Aarhus |
NA |
| NCT00245297 |
Study of the Efficacy of Human Recombinant Factor VIII (Kogenate FS) Reconstituted in Pegylated Liposomes. |
https://ClinicalTrials.gov/show/NCT00245297 |
Completed |
Recoly N.V. |
NA |
| NCT00245245 |
Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIII |
https://ClinicalTrials.gov/show/NCT00245245 |
Completed |
Octagen Corporation |
NA |
| NCT00243659 |
Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery |
https://ClinicalTrials.gov/show/NCT00243659 |
Completed |
Wyeth is now a wholly owned subsidiary of Pfizer |
2008-06-30 |
| NCT00243386 |
Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A |
https://ClinicalTrials.gov/show/NCT00243386 |
Completed |
Shire |
2010-06-30 |
| NCT00221195 |
Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors |
https://ClinicalTrials.gov/show/NCT00221195 |
Completed |
Tulane University |
2009-12-31 |
| NCT00212459 |
The Effect of Patient Counseling on Adolescent Hemophilia Patient Compliance With Bleeding Logs |
https://ClinicalTrials.gov/show/NCT00212459 |
Completed |
New York Presbyterian Hospital |
2006-02-28 |
| NCT00189982 |
Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A - A Continuation of Baxter Study 060101 |
https://ClinicalTrials.gov/show/NCT00189982 |
Completed |
Shire |
NA |
| NCT00168090 |
Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD) |
https://ClinicalTrials.gov/show/NCT00168090 |
Completed |
CSL Behring |
NA |
| NCT00166309 |
The FEIBA NovoSeven Comparative Study |
https://ClinicalTrials.gov/show/NCT00166309 |
Completed |
Skane University Hospital |
NA |
| NCT00162019 |
Pharmacokinetics, Efficacy and Safety Study of IMMUNATE SD (Human Plasma-Derived Coagulation Factor VIII Concentrate) in Hemophilia A Patients |
https://ClinicalTrials.gov/show/NCT00162019 |
Completed |
Shire |
2004-08-31 |
| NCT00157157 |
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients |
https://ClinicalTrials.gov/show/NCT00157157 |
Completed |
Shire |
2009-09-11 |
| NCT00157105 |
Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery |
https://ClinicalTrials.gov/show/NCT00157105 |
Completed |
Shire |
NA |
| NCT00157053 |
Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901 |
https://ClinicalTrials.gov/show/NCT00157053 |
Completed |
Shire |
NA |
| NCT00157040 |
Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A |
https://ClinicalTrials.gov/show/NCT00157040 |
Completed |
Shire |
2005-01-31 |
| NCT00141843 |
Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A |
https://ClinicalTrials.gov/show/NCT00141843 |
Completed |
Wyeth is now a wholly owned subsidiary of Pfizer |
2006-11-30 |
| NCT00139828 |
Post Marketing Study in Haemophilia B Patients Using Nonafact® (Human Coagulation Factor IX) |
https://ClinicalTrials.gov/show/NCT00139828 |
Completed |
Sanquin Plasma Products BV |
NA |
| NCT00108797 |
Trial of NovoSeven® in Haemophilia - Joint Bleeds |
https://ClinicalTrials.gov/show/NCT00108797 |
Completed |
Novo Nordisk A/S |
2006-02-28 |
| NCT00108758 |
Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia |
https://ClinicalTrials.gov/show/NCT00108758 |
Completed |
Novo Nordisk A/S |
2005-11-30 |
| NCT00093210 |
Study Evaluating of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R) in Moderate to Severe Hemophilia B |
https://ClinicalTrials.gov/show/NCT00093210 |
Completed |
Wyeth is now a wholly owned subsidiary of Pfizer |
NA |
| NCT00093171 |
Study Evaluating rFIX; BeneFIX® in Hemophilia B |
https://ClinicalTrials.gov/show/NCT00093171 |
Completed |
Wyeth is now a wholly owned subsidiary of Pfizer |
2005-05-31 |
| NCT00092976 |
Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery |
https://ClinicalTrials.gov/show/NCT00092976 |
Completed |
Wyeth is now a wholly owned subsidiary of Pfizer |
NA |
| NCT00038935 |
Study Evaluating BDDRFVIII and ReFacto AF in Hemophilia A |
https://ClinicalTrials.gov/show/NCT00038935 |
Completed |
Wyeth is now a wholly owned subsidiary of Pfizer |
2003-02-28 |
| NCT00038909 |
Study Evaluating ReFacto in Hemophilia A |
https://ClinicalTrials.gov/show/NCT00038909 |
Completed |
Wyeth is now a wholly owned subsidiary of Pfizer |
2001-05-31 |
| NCT00037557 |
Study Evaluating rFIX; BeneFIX in Severe Hemophilia B |
https://ClinicalTrials.gov/show/NCT00037557 |
Completed |
Wyeth is now a wholly owned subsidiary of Pfizer |
NA |
| NCT00037544 |
Study Evaluating ReFacto AF in Severe Hemophilia A |
https://ClinicalTrials.gov/show/NCT00037544 |
Completed |
Wyeth is now a wholly owned subsidiary of Pfizer |
2004-08-31 |
| NCT00331006 |
Rituximab to Treat Severe Hemophilia A |
https://ClinicalTrials.gov/show/NCT00331006 |
Completed |
HealthCore-NERI |
2010-11-30 |
| NCT00002386 |
Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia |
https://ClinicalTrials.gov/show/NCT00002386 |
Completed |
NIH AIDS Clinical Trials Information Service |
NA |
| NCT00002276 |
The Effects of AZT and Ibuprofen on HIV-Infected Patients With Hemophilia |
https://ClinicalTrials.gov/show/NCT00002276 |
Completed |
NIH AIDS Clinical Trials Information Service |
NA |
| NCT00000705 |
Safety and Effectiveness of Azidothymidine (AZT) in HIV-Positive Patients With Hemophilia |
https://ClinicalTrials.gov/show/NCT00000705 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
NA |
| NCT00000582 |
Cooperative Study of Factor VIII Inhibitors |
https://ClinicalTrials.gov/show/NCT00000582 |
Completed |
National Heart, Lung, and Blood Institute (NHLBI) |
NA |